Measuring the Effect of Cutaneous Neurofibromas on Quality of Life in Neurofibromatosis Type 1.
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
17 08 2021
17 08 2021
Historique:
received:
12
10
2020
accepted:
23
04
2021
pubmed:
8
7
2021
medline:
2
9
2021
entrez:
7
7
2021
Statut:
ppublish
Résumé
In order to explore the use of Skindex scoring in patients with neurofibromatosis type 1 (NF1) across multiple clinical sites and inform design of additional quality of life measures, we analyzed correlations between Skindex, site, and clinical measures for 79 patients with NF1 from specialized clinics in Sydney, Australia (Royal North Shore Hospital [RNS]) and Minneapolis, Minnesota (University of Minnesota [UMN]). The relationship between clinical factors and Skindex scores were explored by clinic site and overall. A total of 40 participants were recruited from RNS and 39 from UMN. Female sex, total number of cutaneous neurofibroma (cNF), and whether cNF were present on the face correlated highly with Skindex and not Riccardi scores. The UMN site had lower average scores, but these differences were almost entirely removed after adjusting for age, sex, facial cNF, and total cNF number. The development of cNF in adolescence and adulthood in NF1 often leads to progressive disfigurement and discomfort and is among one of the most common reasons for patients to seek medical treatment. Skindex has been used to assess skin-related quality of life in NF1 previously but is not specific to NF1. These findings highlight the need for a low threshold for referral to dermatologists for all patients with NF1 regardless of the severity of disease. The finding that facial cNF and higher total number of cNF correlates with poorer skin-related quality of life may benefit design of more specific NF1 skin-related quality of life measures.
Identifiants
pubmed: 34230204
pii: WNL.0000000000012427
doi: 10.1212/WNL.0000000000012427
pmc: PMC8594000
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
S25-S31Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR002494
Pays : United States
Informations de copyright
© 2021 American Academy of Neurology.
Références
J Dermatol. 2018 Jan;45(1):53-57
pubmed: 28891076
J Clin Oncol. 2016 Jun 10;34(17):1978-86
pubmed: 26926675
Dermatology. 2009;218(2):151-4
pubmed: 19060458
Eur J Cancer. 2010 Dec;46(18):3149-57
pubmed: 20869232
J Invest Dermatol. 1996 Nov;107(5):707-13
pubmed: 8875954
Am J Med Genet A. 2006 Sep 15;140(18):1893-8
pubmed: 16906549
Genet Med. 2018 Jul;20(7):671-682
pubmed: 30006586
J Invest Dermatol. 2019 May;139(5):1037-1044
pubmed: 30481495
Birth Defects Orig Artic Ser. 1977;13(3C):131-8
pubmed: 407957
J Neurooncol. 2015 Apr;122(2):219-28
pubmed: 25663248
Acta Derm Venereol. 2018 Aug 29;98(8):753-756
pubmed: 29796689
Dermatology. 2009;218(3):215-20
pubmed: 19088462
Am J Med Genet A. 2016 Jun;170(6):1462-70
pubmed: 27021207
Neurology. 2009 Oct 20;73(16):1273-9
pubmed: 19841379
J Genet Couns. 2015 Dec;24(6):931-44
pubmed: 25894096
J Dermatol. 2018 May;45(5):626-627
pubmed: 29696709
Arch Dermatol. 1997 Nov;133(11):1433-40
pubmed: 9371029
Arch Dermatol. 2001 Nov;137(11):1421-5
pubmed: 11708944
Handb Clin Neurol. 2018;148:799-811
pubmed: 29478615
Dermatology. 2011;222(3):269-73
pubmed: 21540571
Eur J Dermatol. 2018 Dec 1;28(6):775-783
pubmed: 30698147